Counterweight Ventures LLC Has $1.05 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

Counterweight Ventures LLC lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 22.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 20,232 shares of the biopharmaceutical company’s stock after selling 5,841 shares during the period. Counterweight Ventures LLC’s holdings in Bristol-Myers Squibb were worth $1,047,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bessemer Group Inc. increased its position in Bristol-Myers Squibb by 16.3% in the 1st quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company’s stock valued at $8,625,000 after buying an additional 22,286 shares in the last quarter. Lake Street Advisors Group LLC increased its holdings in shares of Bristol-Myers Squibb by 54.7% during the first quarter. Lake Street Advisors Group LLC now owns 13,530 shares of the biopharmaceutical company’s stock valued at $734,000 after acquiring an additional 4,784 shares in the last quarter. Pitcairn Co. raised its position in shares of Bristol-Myers Squibb by 152.3% during the first quarter. Pitcairn Co. now owns 48,250 shares of the biopharmaceutical company’s stock worth $2,617,000 after purchasing an additional 29,128 shares during the period. Ossiam lifted its holdings in shares of Bristol-Myers Squibb by 31.7% in the 1st quarter. Ossiam now owns 88,183 shares of the biopharmaceutical company’s stock worth $4,782,000 after purchasing an additional 21,234 shares in the last quarter. Finally, Leelyn Smith LLC lifted its stake in shares of Bristol-Myers Squibb by 4.6% in the first quarter. Leelyn Smith LLC now owns 38,525 shares of the biopharmaceutical company’s stock valued at $2,089,000 after buying an additional 1,681 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. This represents a 5.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Samit Hirawat bought 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.4 %

BMY opened at $56.60 on Tuesday. The business has a 50 day moving average of $52.90 and a 200-day moving average of $47.37. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.00 earnings per share. As a group, research analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a $0.60 dividend. The ex-dividend date was Friday, October 4th. This represents a $2.40 annualized dividend and a yield of 4.24%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -66.85%.

Analysts Set New Price Targets

A number of research firms have issued reports on BMY. TD Cowen lifted their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. BMO Capital Markets lifted their price objective on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Finally, StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $54.07.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.